Since the initial discovery of the role of histamine in allergic conditions (1) serious efforts have been made to develop drugs that inhibit the actions of histamine. Already in 1933, Fourneau and Bovet (2) reported the first "antihistamine" piperoxan. Following this finding many potent H 1 antagonists that can be considered as variations of diaryl-substituted ethylamines (e.g. diphenhydramine and mepyramine) have been developed (for review see Ref.
Since the initial discovery of the role of histamine in allergic conditions (1) serious efforts have been made to develop drugs that inhibit the actions of histamine. Already in 1933, Fourneau and Bovet (2) reported the first "antihistamine" piperoxan. Following this finding many potent H 1 antagonists that can be considered as variations of diaryl-substituted ethylamines (e.g. diphenhydramine and mepyramine) have been developed (for review see Ref. 3) . These "first generation" H 1 antagonists are quite effective in humans in allergic rhinitis and urticaria, but because of central nervous system penetration and central H 1 receptor blockade their clinical use is hampered by sedative side effects (3) (4) (5) . A "second generation" of nonsedative H 1 antagonists (e.g. astemizole, acrivastine, cetirizine, loratidine, and terfenadine) has recently been developed (for review see Ref. 3) . Their altered pharmacokinetics result in good clinical effectiveness combined with a strongly reduced sedative potential (3) (4) (5) .
The development of H 1 antagonists has so far been directed by traditional medicinal chemistry (3) . With the availability of the genetic information of the histamine H 1 receptor (6), the rationalization of drug-protein interaction has become a major challenge for this therapeutically important class of drugs. Like all aminergic G-protein coupled receptors (GPCR), 1 the H 1 receptor contains an aspartate residue (Asp 116 ) in transmembrane domain (TM) III (6) , that is involved in the binding of the protonated amine function found in both agonists and antagonists structures (7, 8) . Mutagenesis studies have furthermore shown that the imidazole ring of histamine is accommodated by Lys 200 and Asn 207 in TM V (9, 10) . In view of the low sequence similarity between GPCRs and bacteriorhodopsin (BR) much controversy exists on the validity of models derived for GPCRs based on the homology with BR (11) (12) (13) . Nevertheless, despite the speculative nature of BRderived GPCR models they have been quite helpful in understanding and predicting drug-receptor interactions for a variety of receptors (see e.g. Refs. 14 -16) . Previously, we also developed a three-dimensional computer model of the histamine H 1 receptor based on the homology with BR, incorporating the results obtained from mutagenesis studies on the agonist binding site (17) . In the present study this computer model of the H 1 receptor was combined with a pharmacophoric model of the H 1 antagonistic binding site (18) . This ligand-based model for the H 1 antagonistic binding site is based upon an interaction of the protonated amine function of various first generation, semi-rigid H 1 antagonists with an aspartate residue (Asp 116 in the guinea pig H 1 receptor) (18) and precisely positions the cis-and trans-aromatic rings of the H 1 antagonists relative to the C ␣ and C ␤ carbon atoms of this aspartate residue. Combining the three-dimensional receptor model and the ligand-based pharmacophoric model of the H 1 antagonist binding site resulted in the prediction of interactions of aromatic amino acids in TM IV and VI with the H 1 antagonists. Subsequently, we experimentally confirmed the involvement of these predicted amino acids in the binding of the H 1 antagonist [ 3 H]mepyramine by site-directed mutagenesis. Moreover, on the basis of the three-dimensional model of the antagonistreceptor complex, a specific interaction of carboxylate moieties of therapeutically important, second generation zwitterionic H 1 antagonists (acrivastine and cetirizine) with Lys 200 in TM V was predicted and experimentally verified.
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EXPERIMENTAL PROCEDURES
Materials-Bovine serum albumin, DEAE-dextran, polyethyleneimine, and triprolidine hydrochloride were obtained from Sigma. The mouse anti-FLAG M2 monoclonal antibody was obtained from International Biotechnology Inc. The fluorescein isothiocyanate-conjugated rabbit-anti-mouse secondary antibody was supplied by Dakopatts AB (Stockholm, Sweden). [ 3 H]Mepyramine (28 Ci/mmol) was obtained from Amersham Pharmacia Biotech. Gifts of acrivastine (The Wellcome Foundation Ltd., London, United Kingdom), d-cetirizine hydrochloride, meclozine hydrochloride (UCB, Braine-l'Alleud, Belgium), and mianserin hydrochloride (Organon NV, Oss, the Netherlands) are gratefully acknowledged.
Predicition of Ligand-Receptor Interactions-H 1 antagonists were docked in the previously described three-dimensional receptor model of the guinea pig H 1 receptor (17), using the rigid H 1 antagonist pharmacophoric model of Ter Laak et al. (18) . This model describes the threedimensional topology of the cis-and trans-aromatic rings of cyproheptadine with respect to the positions of the C ␣ and C ␤ carbon atoms of an putative Asp residue from the receptor (see Fig. 1A ). The C ␣ and C ␤ carbon atoms of the pharmacophore replaced the corresponding atoms of Asp 116 in the receptor model. Rotation was carried out along the C ␣ -C ␤ bond until cyproheptadine was positioned in the receptor in an energetically favorable orientation. The structure of the zwitterionic compounds acrivastine and d-cetirizine were built and optimized with Chem-X and subsequently docked into the H 1 receptor model onto the cyproheptadine template as described previously (18) . Subsequently, all freely rotatable bonds in Lys 200 and in the side chains of the zwitterionic H 1 antagonist were taken into account in an extensive conformational analysis (MacroModel/AMBER force field (19) ).
Site-directed Mutagenesis-The guinea pig H 1 receptor cDNA was subcloned in the pALTER vector (Promega), and point mutations were introduced according to the manufacturer's protocol. The wild type and mutant receptors were epitope-tagged with an N-terminal FLAG peptide (DYKDDDD) after modification of the cDNA sequence with polymerase chain reaction. In our initial binding studies (see Fig. 2 ) nontagged receptors were used. The cDNA sequences were verified using the dideoxy chain termination method with the Sequenase kit (U. S. Biochemical Corp.).
Cell Culture and Transfection-COS-7 and HEK-293 cells were grown at 37°C in a humidified atmosphere with 5% CO 2 in Dulbecco's modified Eagle's medium, containing 2 mM L-glutamine, 50 IU/ml penicillin, 50 g/ml streptomycin, and 5 or 10% (v/v) fetal calf serum, respectively. Cells were transiently transfected with pcDNA3, containing the wild type or mutant H 1 receptor cDNA, using DEAE-dextran (COS-7 cells) or calcium phosphate (HEK-293 cells). 3 H]mepyramine and increasing concentrations of competing ligands. The incubations were stopped by rapid dilution with 3 ml of ice-cold 50 mM Na 2 /potassium phosphate buffer (pH 7.4). The bound radioactivity was separated by filtration through Whatman GF/C filters that had been treated with 0.3% polyethyleneimine. Filters were washed twice with 3 ml of buffer, and radioactivity retained on the filters was measured by liquid scintillation counting. The binding data were evaluated by a nonlinear, least squares curve fitting procedure. Protein levels were determined according to Bradford (20) , using bovine serum albumin as standard.
[ 3 H]Inositol Phosphate Production-HEK-293 cells were seeded in 12-well plates and 24 h after transfection labeled overnight in inositolfree culture medium supplemented with 2 Ci/ml myo- [2- 3 H]inositol. Cells were stimulated for 1 h at 37°C with Dulbecco's modified Eagle's medium containing 25 mM Hepes (pH 7.4), 20 mM LiCl, and histamine. The incubation was stopped by aspiration of the culture medium and the addition of cold CHCl 3 /methanol (1:2 v/v). After extraction with water, [ 3 H]inositol phosphates were isolated by anion exchange chromatography (21) .
Immunofluorescence-Transfected COS-7 cells were grown on glass coverslips and after 48 h fixed with 4% paraformaldehyde/phosphatebuffered saline for 30 min at room temperature and blocked in phosphate-buffered saline/0.1% bovine serum albumin for 1 h at room temperature. Antigen detection was performed as described (22) . ) and Trp 167 in TM IV (Fig. 1B ). All these predicted residues are conserved in all the reported H 1 receptor sequences (23) (24) (25) (26) (27) (28) (29) (Fig. 2) Using confocal laser microscopy we identified specific, anti-FLAG immunofluorescence in the plasma membrane of COS-7 cells expressing the epitope-tagged wild type and the Phe 433 3 Ala H 1 receptor (Fig. 3) (Fig. 4) , whereas after overexpression of the epitope-tagged wild type H 1 receptor protein (7.1 Ϯ 1.0 pmol/mg protein, mean Ϯ S.E., n ϭ 3) histamine (100 M) stimulated the [ 3 H]inositol phosphate accumulation 5.9 Ϯ 0.4-fold (mean Ϯ S.E., n ϭ 3) over basal levels (Fig. 4) (Fig. 4) 433 3 Ala mutant no radioligand binding was found. As expected by the perturbed membrane expression, the Trp 161 3 Ala receptor mutant did not respond to histamine (Fig. 4) pmol/mg protein, means Ϯ S.E., n ϭ 3). Despite its low expression level a significant stimulation (Fig. 4) of the mutant receptor by histamine was observed with comparable potency as the wild type receptor (Table I) . For the various mutations of Trp 167 only the Trp 167 3 Phe mutation resulted in a mutant receptor that could be activated by histamine, although with a very low efficacy (Fig. 4 and (Fig. 5A ). In the case of d-cetirizine, the carboxylate group is attached to the basic nitrogen via a long ether chain. Docking cetirizine in the H 1 receptor model indicated that the carboxylate of d-cetirizine reaches the proximity of Lys 200 , although the calculated N-O distance of 3.57 Å is somewhat large for a strong (ionic) hydrogen bond interaction (Fig. 5B) .
RESULTS

Prediction of Ligand-Receptor Interaction Based on Receptor
Interaction Table II ). In contrast, acrivastine still showed high affinity for the Lys 200 3 Arg receptor mutant (Fig. 6A and Table II) . To further substantiate these findings we tested the affinity of triprolidine, a structural analog of acrivastine lacking the carboxylate moiety (Table III) , for the Lys 200 3 Ala receptor mutant. As expected, the affinity of this close structural analog was not reduced by the Lys 200 3 Ala mutation (Fig. 6B and Table III ). The Lys 200 residue is also involved in a specific interaction with the nonsedative, zwitterionic H 1 antagonist d-cetirizine (Fig. 6C and Table III) . Again, no effect of the Lys 200 3 Ala mutation was found on the affinity of the analog meclozine, which does not contain a functional group that can interact with the Lys 200 residue in TM V ( Fig.  6C and Table III) .
DISCUSSION
More than 25 years after the initial hypothesis of Nauta et al. (30) of an interaction of the trans-aromatic ring of the H 1 antagonist diphenhydramine with a Phe residue of an hypothetical ␣-helical structure of the H 1 receptor, we identified the aromatic amino acids Trp 167 , Phe 433 , and Phe 436 in the putative ␣-helical TMs IV and VI of the H 1 receptor as probable interaction points for the trans-aromatic ring of the H 1 antagonists. Moreover, we found Lys 200 (TM V) to be a specific anchor point for the carboxylate moiety of the nonsedative, zwitterionic second generation H 1 antagonists acrivastine and cetirizine.
The basis for the identification of these amino acids came from the docking of an H 1 antagonistic pharmacophoric model (18) into a previously derived three-dimensional model of the H 1 receptor (17) . As a representative example of the first generation H 1 antagonists, the rigid tricyclic cyproheptadine was allowed to interact with its protonated amine function with the highly conserved Asp 116 in TM III (7, 8) . Several aromatic amino acid residues were predicted to interact with the aro- (40) . We can therefore not exclude the possibility that a hydrophobic amino acid at position 161 is simply essential to adopt a functional GPCR conformation.
Based on the results of the site-directed mutagenesis studies we concluded that the three-dimensional H 1 In view of the emerging cardiotoxicity of several second generation H 1 antagonists (41) and the current interest to combine potent nonsedative H 1 antagonism with other anti-allergic activities (3), the identification of the role of Lys 200 will be of importance for the design of potent "third generation" H 1 antagonists. The introduction of an carboxylate group in the structure of the H 1 antagonists has by empirical approach been found to be a very effective way to limit central nervous system penetration and to derive nonsedative H 1 antagonists like acrivastine (42) and cetirizine (43 
